Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Chief Medical Officer | May 22, 2020 | May 26, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date May 22, 2020 · Filed May 26, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,459 |
Reported balance
After 2020-05-22 transaction · row 1
1 source rowRow 1 · 2020-05-22 · Exercise / conversion · Acquired 20,000 · Balance 31,459 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2026-01-17 | Direct | 51,584 |
Reported balance
After 2020-05-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-22 · Exercise / conversion · Disposed 20,000 · Balance 51,584 F1: The shares subject to the option are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2020 Filed May 26, 2020 20:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001447362-20-000082 · wf-form4_159052388689095.xml · derivative · entry 2 Monzon Federico A. · CIK 0001783133 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,584 Underlying: Common Stock · 20,000 shares Expires 2026-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| May 22, 2020 Filed May 26, 2020 20:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 20,000 | $1.92 | $38,400.00 |
DisclosureSEC source: 0001447362-20-000082 · wf-form4_159052388689095.xml · nonDerivative · entry 1 Monzon Federico A. · CIK 0001783133 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $29.50 | $0.00 |
DisclosureSEC source: 0001447362-19-000023 · wf-form4_157661713679209.xml · derivative · entry 1 Monzon Federico A. · CIK 0001783133 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-12-12 F1 · derivative.exercise_date: 25% of the shares shall vest on December 13, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.